Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study
| Autor: | Rafael Salazar, Jordi Guitart, María Isabel Vargas, José Fuentes, Vicente De Sanctis, Francisco Rodelas, Julia Ferreras, Joan Coma, Pere Estivill, Albert Tomás, Antonio Javier Jiménez, Jordi Moya, Jordi Folch, Almudena Sanz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
humanos
depresión Anxiety Fentanyl 0302 clinical medicine Quality of life analgésicos Neoplasms estudios prospectivos Original Research Article 030212 general & internal medicine Prospective Studies Prospective cohort study Depression (differential diagnoses) mediana edad neoplasias Analgesics anciano Depression Age Factors fentanilo Cancer Pain Middle Aged Analgesics Opioid escalas de valoración psiquiátrica Anesthesia dolor intercurrente medicine.drug Tablets medicine.medical_specialty Administration Sublingual Subgroup analysis 03 medical and health sciences Pharmacotherapy Internal medicine medicine Humans Aged Pharmacology Psychiatric Status Rating Scales business.industry Breakthrough Pain Cancer ansiedad medicine.disease Spain calidad de vida Quality of Life comprimidos Cancer pain business 030217 neurology & neurosurgery |
| Zdroj: | Drugs in R&D |
| Popis: | Introduction Breakthrough pain (BTP) management in patients with cancer is challenging, especially in the elderly. However, no studies examining the influence of age on BTP medication have been conducted. The aim of this work was to investigate the effect of sublingual fentanyl tablets (SFTs) in terms of efficacy, safety, and quality of life in two age categories. Methods We performed age subgroup analyses (= 65 years. SF-12v2 scores did not enhance significantly from baseline. HADS scores and PI decreased significantly at the end of the study, particularly in younger patients (HADS-A: 19.05 vs. 14.41%; HADS-D: 21.35 vs. 18.57%; PI: 67.23 vs. 56.30%). Onset of analgesia began in 2-5 min in 63.3% of subjects aged 65 years. Most patients experienced one to five daily episodes after 30 days, and This study was funded by Kyowa Kirin Farmaceutica, S.L.U. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|